Wills Eye Institute receives IRB approval to treat dry-AMD using ACT’s hESC-derived retinal pigment epithelial (RPE) cells MARLBOROUGH, Mass. —…
WORCESTER, Mass.– (BUSINESS WIRE)–Advanced Cell Technology, Inc. (Advanced Cell, ACT) (OTC: ACTC – News) and a leading leading Korea-based stem cell company, CHA…
MARLBOROUGH, Mass. –Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC or the “Company”), a leader in the field of regenerative medicine, announced…
Company is Halfway through Groundbreaking Clinical Trials; Evidence of Engraftment and Function Observed; No Safety Issues Reported MARLBOROUGH, Mass. —…
Patient Injected with 100,000 human embryonic stem cell-(hESC) derived Retinal Pigment Epithelial Cells MARLBOROUGH, Mass. — April 15, 2013 –…
MARLBOROUGH, MA –July 27, 2010 (BUSINESS WIRE). Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC) announced today that it has submitted documentation and a…
Leading Eye Institute Will Participate as Site for Both of ACT’s Phase I/II Clinical Trials Using Human Embryonic Stem Cell-Derived…
Worcester, MA / La Jolla, CA – Advanced Cell Technology, Inc. (OTCBB:ACTC.OB) announced today it has entered into a research…
Final Patient from First Cohort Treated with ESC-Derived RPE Cells in Dry AMD Phase I/II U.S. Trial MARLBOROUGH, Mass. —…
Second Site for First Human Embryonic Stem Cell Trial in Europe MARLBOROUGH, Mass. — Jan. 30, 2012 – Advanced Cell…